monoclonal antibodies and rituximab Archives

Abstract Number: 1675 • ACR/ARHP Annual Meeting 2015
Efficacy and Safety of Switched CT-P10 from Innovator Rituximab Compared to Those of Maintained CT-P10 in Patients with Rheumatoid Arthritis up to 56 Weeks
Dae-Hyun Yoo¹, Won Park², Chang-Hee Suh³, Seung-Cheol Shim⁴, Fidencio Cons Molina⁵, Slawomir Jeka⁶, Jan Brzezicki⁷, Francisco G. Medina-Rodriguez⁸, Pawel Hrycaj⁹, Piotr Wiland¹⁰, Eun Young Lee¹¹, Pavel Shesternya¹², Volodymyr Kovalenko¹³, Leysan Myasoutova¹⁴, Marina Stanislav¹⁵, Sebastiao Radominski¹⁶, Mie Jin Lim¹⁷, Jung-Yoon Choe¹⁸, Sung Young Lee¹⁹ and Sang Joon Lee²⁰, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, ⁴Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ⁵Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁶University Hospital Nr 2 Dr. Jan Biziel, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Clinic of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, ⁷Wojewodzki Szpital Zespolony w Elablagu, Elblag, Poland, ⁸Rheumatology, LaSalle University, Mexico City, Mexico, ⁹Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ¹⁰Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ¹¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ¹²Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹³Section of Non-coronarogenic Myocardial Diseases and Clinical Rheumatology, National Scientific Center, Kiev, Ukraine, ¹⁴City Reumatology Center, Research Medical Complex Vashe Zdorovie, Kazan, Russia, ¹⁵Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia, ¹⁶CETI-Centro de estudos em Terapias Inovadoras, Universidade Federal do Parana, Curitiba, Brazil, ¹⁷Division of Rheumatology, Departments of Internal Medicine, Inha University Hospital, Incheion, South Korea, ¹⁸Internal Medicine, Catholic University of Daegu, School of Medicine, Daegu, South Korea, ¹⁹Clinical Planning Department, CELLTRION, Inc., Incheon, South Korea, ²⁰CELLTRION, Inc., Incheon, South Korea
Background/Purpose: Pharmacokinetic (PK) equivalence and similarity of clinical efficacy, safety and immunogenicity up to week 24 were demonstrated between CT-P10, a biosimilar candidate for innovator…
Abstract Number: 1955 • ACR/ARHP Annual Meeting 2014
Disparity in Internalisation of Monoclonal Antibodies Targeting B Cell Antigens and Regulation By Fc Gamma Receptor IIb: Implications for Targeted Therapy in SLE
Venkat Reddy¹, Geraldine Cambridge², David A. Isenberg³, Mark Cragg⁴ and Maria J. Leandro², ¹Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom
Background/Purpose Monoclonal antibodies (mAbs) targeting B cell antigens CD20 and CD22 are used to treat patients with SLE either in the clinic or in clinical…
Abstract Number: 745 • ACR/ARHP Annual Meeting 2013
Rate Of Infection and Development Of Malignancy In Patients With ANCA-Associated Vasculitis Treated With Rituximab: A Meta-Analysis From Randomized Trials
Carolina Mejia-Otero¹, Carlos J. Lozada² and Luis Arias-Urdaneta³, ¹Internal Medicine, Mount Sinai Medical Center, Miami, FL, ²Dept of Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ³Rheumatology, Mount Sinai Medical Center, Miami Beach, FL
Background/Purpose: Over the past 40 years failures to achieve remission in a proportion of patients and the potential development of significant adverse effects have been…
Abstract Number: 835 • ACR/ARHP Annual Meeting 2012
Low Doses of Ocaratuzumab, a Fc- and Fab-Engineered Anti-CD20 Antibody, Result in Rapid and Sustained Depletion of Circulating B-Cells in Rheumatoid Arthritis Patients
Adrienne O'Reilly, Tracy Davis and Vinay Jain, Mentrik Biotech, Dallas, TX
Background/Purpose: B-cell depletion provides therapeutic benefits for patients with rheumatoid arthritis (RA). Ocaratuzumab, previously known as AME-133v, is a Fc- and Fab-engineered, humanized, anti-CD20…

Abstracts tagged "monoclonal antibodies and rituximab"

Efficacy and Safety of Switched CT-P10 from Innovator Rituximab Compared to Those of Maintained CT-P10 in Patients with Rheumatoid Arthritis up to 56 Weeks

Disparity in Internalisation of Monoclonal Antibodies Targeting B Cell Antigens and Regulation By Fc Gamma Receptor IIb: Implications for Targeted Therapy in SLE

Rate Of Infection and Development Of Malignancy In Patients With ANCA-Associated Vasculitis Treated With Rituximab: A Meta-Analysis From Randomized Trials

Low Doses of Ocaratuzumab, a Fc- and Fab-Engineered Anti-CD20 Antibody, Result in Rapid and Sustained Depletion of Circulating B-Cells in Rheumatoid Arthritis Patients